Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 14;7:8036. doi: 10.1038/s41598-017-08176-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

OipA increases cleaved-caspase 3 and Bax/Bcl-2 ratio in AGS and KATO III, but does not have any effect on caspase 8 and FasL. Western blot analysis was performed for determination of caspase 3, 8, FasL and Bax/Bcl-2 ratio in OipA treated AGS and KATO III. Samples were treated with BSA or heat-inactivated OipA as negative controls or 20 μg/mL or 40 μg/ml of OipA for 24 h. Representative pictures showing the level of cleaved-caspase 3, pro-caspase 8, FasL, β-actin, Bcl-2 and Bax (A). Densitometric analysis showing the levels of caspase 3, 8, FasL, Bcl-2, Bax in AGS (B) and KATO III (D) and Bax/Bcl-2 ratio in AGS (C) and KATO III (E) in all treatment groups. The results are expressed as the mean ± SD, (n = 3, three independent experiments). Statistically significant differences with the control groups are indicated with *(p < 0.05).